Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
471.313729561
InChI
InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3
InChI Key
InChIKey=GUGOEEXESWIERI-UHFFFAOYSA-N
IUPAC Name
1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol
Traditional IUPAC Name
terfenadine
SMILES
CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Độ hòa tan
0.0963 mg/L (at 25 °C)
pKa (strongest acidic)
13.2
pKa (Strongest Basic)
9.02
Refractivity
146.27 m3·mol-1
Dược Lực Học :
Terfenadine, an H1-receptor antagonist antihistamine, is similar in structure to astemizole and haloperidol, a butyrophenone antipsychotic. The active metabolite of terfenadine is fexofenadine.
Cơ Chế Tác Dụng :
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Terfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal.
Dược Động Học :
▧ Absorption :
On the basis of a mass balance study using 14C labeled terfenadine the oral absorption of terfenadine was estimated to be at least 70%
▧ Protein binding :
70%
▧ Metabolism :
Hepatic
▧ Half Life :
3.5 hours
Độc Tính :
Mild (e.g., headache, nausea, confusion), but adverse cardiac events including cardiac arrest, ventricular arrhythmias including torsades de pointes and QT prolongation have been reported. LD50=mg/kg (orally in mice)
Chỉ Định :
For the treatment of allergic rhinitis, hay fever, and allergic skin disorders.
Tương Tác Thuốc :
-
Acetophenazine
Increased risk of cardiotoxicity and arrhythmias
-
Alimemazine
Increased risk of cardiotoxicity and arrhythmias
-
Amiodarone
Increased risk of cardiotoxicity and arrhythmias
-
Amitriptyline
Increased risk of cardiotoxicity and arrhythmias
-
Amoxapine
Increased risk of cardiotoxicity and arrhythmias
-
Amprenavir
Increased risk of cardiotoxicity and arrhythmias
-
Aprepitant
Increased risk of cardiotoxicity and arrhythmias
-
Bepridil
Increased risk of cardiotoxicity and arrhythmias
-
Chlorpromazine
Increased risk of cardiotoxicity and arrhythmias
-
Cimetidine
Increased risk of cardiotoxicity and arrhythmias
-
Cisapride
Increased risk of cardiotoxicity and arrhythmias
-
Clarithromycin
Increased risk of cardiotoxicity and arrhythmias
-
Clomipramine
Increased risk of cardiotoxicity and arrhythmias
-
Delavirdine
Increased risk of cardiotoxicity and arrhythmias
-
Desipramine
Increased risk of cardiotoxicity and arrhythmias
-
Diltiazem
Increased risk of cardiotoxicity and arrhythmias
-
Disopyramide
Increased risk of cardiotoxicity and arrhythmias
-
Doxepin
Increased risk of cardiotoxicity and arrhythmias
-
Efavirenz
Increased risk of cardiotoxicity and arrhythmias
-
Erythromycin
Increased risk of cardiotoxicity and arrhythmias
-
Flecainide
Increased risk of cardiotoxicity and arrhythmias
-
Fluconazole
Increased risk of cardiotoxicity and arrhythmias
-
Fluoxetine
Increased risk of cardiotoxicity and arrhythmias
-
Fluphenazine
Increased risk of cardiotoxicity and arrhythmias
-
Fluvoxamine
Increased risk of cardiotoxicity and arrhythmias
-
Fosamprenavir
Increased risk of cardiotoxicity and arrhythmias
-
Grepafloxacin
Increased risk of cardiotoxicity and arrhythmias
-
Imipramine
Increased risk of cardiotoxicity and arrhythmias
-
Indinavir
Increased risk of cardiotoxicity and arrhythmias
-
Itraconazole
Increased risk of cardiotoxicity and arrhythmias
-
Josamycin
Increased risk of cardiotoxicity and arrhythmias
-
Ketoconazole
Increased risk of cardiotoxicity and arrhythmias
-
Mesoridazine
Increased risk of cardiotoxicity and arrhythmias
-
Methdilazine
Increased risk of cardiotoxicity and arrhythmias
-
Methotrimeprazine
Increased risk of cardiotoxicity and arrhythmias
-
Mexiletine
Increased risk of cardiotoxicity and arrhythmias
-
Mibefradil
Increased risk of cardiotoxicity and arrhythmias
-
Nefazodone
Increased risk of cardiotoxicity and arrhythmias
-
Nelfinavir
Increased risk of cardiotoxicity and arrhythmias
-
Nicardipine
Increased risk of cardiotoxicity and arrhythmias
-
Nortriptyline
Increased risk of cardiotoxicity and arrhythmias
-
Perphenazine
Increased risk of cardiotoxicity and arrhythmias
-
Posaconazole
Contraindicated co-administration
-
Procainamide
Increased risk of cardiotoxicity and arrhythmias
-
Prochlorperazine
Increased risk of cardiotoxicity and arrhythmias
-
Promazine
Increased risk of cardiotoxicity and arrhythmias
-
Promethazine
Increased risk of cardiotoxicity and arrhythmias
-
Propafenone
Increased risk of cardiotoxicity and arrhythmias.
-
Propericiazine
Increased risk of cardiotoxicity and arrhythmias
-
Propiomazine
Increased risk of cardiotoxicity and arrhythmias
-
Protriptyline
Increased risk of cardiotoxicity and arrhythmias
-
Quinidine
Increased risk of cardiotoxicity and arrhythmias
-
Quinine
Increased risk of cardiotoxicity and arrhythmias
-
Quinupristin
This combination presents an increased risk of toxicity
-
Ritonavir
Increased risk of cardiotoxicity and arrhythmias
-
Saquinavir
Increased risk of cardiotoxicity and arrhythmias
-
Sotalol
Increased risk of cardiotoxicity and arrhythmias
-
Sparfloxacin
Increased risk of cardiotoxicity and arrhythmias
-
Telavancin
Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
-
Telithromycin
Increased risk of cardiotoxicity and arrhythmias
-
Thiethylperazine
Increased risk of cardiotoxicity and arrhythmias
-
Thioridazine
Increased risk of cardiotoxicity and arrhythmias
-
Tipranavir
Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Terfenadine. Concomitant therapy is contraindicated.
-
Tocainide
Increased risk of cardiotoxicity and arrhythmias
-
Trifluoperazine
Increased risk of cardiotoxicity and arrhythmias
-
Triflupromazine
Increased risk of cardiotoxicity and arrhythmias
-
Trimipramine
Increased risk of cardiotoxicity and arrhythmias
-
Troleandomycin
Increased risk of cardiotoxicity and arrhythmias
-
Verapamil
Increased risk of cardiotoxicity and arrhythmias
-
Voriconazole
Increased risk of cardiotoxicity and arrhythmias
Liều Lượng & Cách Dùng :
Tablet - Oral
Dữ Kiện Thương Mại
Nhà Sản Xuất
-
Sản phẩm biệt dược : Bronal
-
Sản phẩm biệt dược : Daylert
-
Sản phẩm biệt dược : Seldane
-
Sản phẩm biệt dược : Servinin
-
Sản phẩm biệt dược : Teldane
-
Sản phẩm biệt dược : Terfed
-
Sản phẩm biệt dược : Terfenadin AL
-
Sản phẩm biệt dược : Terfenadine FLX
-
Sản phẩm biệt dược : Terfin
-
Sản phẩm biệt dược : Ternadin
-
Sản phẩm biệt dược : Trexyl
-
Sản phẩm biệt dược : Triludan